Liquidia Corporation Announces CEO Dr. Roger Jeffs to Present at 44th Annual J.P. Morgan Healthcare Conference

Liquidia Corporation's CEO will present at the J.P. Morgan Healthcare Conference on January 14, 2026. Webcast available online.

Quiver AI Summary

Liquidia Corporation has announced that its CEO, Dr. Roger Jeffs, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 p.m. Pacific Time in San Francisco. The presentation will be accessible via a live audio-only webcast on the "Investors" page of Liquidia's website, with an archived version available for at least 30 days. Liquidia is a biopharmaceutical company focused on developing innovative therapies for respiratory and vascular diseases, using its proprietary PRINT® Technology. The company has released its first approved product, YUTREPIA™ (treprostinil) inhalation powder, for pulmonary arterial hypertension and is also working on other formulations of treprostinil, including L606, an investigational extended-release version.

Potential Positives

Dr. Roger Jeffs, the CEO, is presenting at the prestigious 44th Annual J.P. Morgan Healthcare Conference, which enhances the company's visibility in the healthcare sector.
The presentation will include an audio-only webcast, allowing wider access to Liquidia's information for investors and interested parties.
The company is positioned as an innovator in biopharmaceuticals, particularly with its proprietary PRINT® Technology, which underscores its commitment to advancing treatments for respiratory and vascular diseases.
Liquidia's first approved product, YUTREPIA™, signifies the company's successful entry into the market with a treatment for serious conditions like pulmonary arterial hypertension.

Potential Negatives

None

FAQ

When is Dr. Roger Jeffs presenting at the J.P. Morgan Healthcare Conference?

Dr. Roger Jeffs will present on January 14, 2026, at 5:15 p.m. Pacific Time.

How can I access the Liquidia presentation webcast?

The presentation webcast can be accessed on the “Investors” page of Liquidia’s website.

What product did Liquidia Corporation create using PRINT® Technology?

Liquidia’s first approved product using PRINT® Technology is YUTREPIA™ for treating pulmonary arterial hypertension.

What is L606 developed by Liquidia Corporation?

L606 is an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer.

Where can I find more information about Liquidia Corporation?

More information about Liquidia Corporation can be found on their official website at www.liquidia.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$LQDA Insider Trading Activity

$LQDA insiders have traded $LQDA stock on the open market 50 times in the past 6 months. Of those trades, 0 have been purchases and 50 have been sales.

Here’s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:

PAUL B MANNING has made 0 purchases and 4 sales selling 670,837 shares for an estimated $18,957,475.
RAJEEV SAGGAR (Chief Medical Officer) has made 0 purchases and 6 sales selling 104,561 shares for an estimated $2,721,861.
SCOTT MOOMAW (Chief Commercial Officer) has made 0 purchases and 6 sales selling 81,220 shares for an estimated $2,233,630.
JASON ADAIR (Chief Business Officer) has made 0 purchases and 8 sales selling 70,249 shares for an estimated $1,979,412.
MICHAEL KASETA (CFO and COO) has made 0 purchases and 5 sales selling 74,376 shares for an estimated $1,598,960.
RAMAN SINGH has made 0 purchases and 2 sales selling 53,024 shares for an estimated $1,395,624.
ROGER JEFFS (Chief Executive Officer) has made 0 purchases and 3 sales selling 60,765 shares for an estimated $1,052,707.
DANA BOYLE (Chief Accounting Officer) has made 0 purchases and 7 sales selling 33,874 shares for an estimated $828,820.
RUSSELL SCHUNDLER (General Counsel) has made 0 purchases and 4 sales selling 17,810 shares for an estimated $360,796.
JOANNA HOROBIN sold 5,000 shares for an estimated $135,850
SARAH KREPP (Chief Human Resource Officer) has made 0 purchases and 4 sales selling 4,794 shares for an estimated $90,942.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$LQDA Revenue

$LQDA had revenues of $54.3M in Q3 2025. This is an increase of 1121.72% from the same period in the prior year.

You can track LQDA financials on Quiver Quantitative's LQDA stock page.

$LQDA Hedge Fund Activity

We have seen 114 institutional investors add shares of $LQDA stock to their portfolio, and 88 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FARALLON CAPITAL MANAGEMENT LLC added 4,326,876 shares (+102.1%) to their portfolio in Q3 2025, for an estimated $98,393,160
TCG CROSSOVER MANAGEMENT, LLC added 1,710,084 shares (+inf%) to their portfolio in Q3 2025, for an estimated $38,887,310
CAPROCK GROUP, LLC added 1,632,089 shares (+inf%) to their portfolio in Q3 2025, for an estimated $37,113,703
DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,616,778 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $36,765,531
JANUS HENDERSON GROUP PLC removed 1,603,977 shares (-98.3%) from their portfolio in Q3 2025, for an estimated $36,474,436
D. E. SHAW & CO., INC. added 1,341,462 shares (+916.1%) to their portfolio in Q3 2025, for an estimated $30,504,845
TYRO CAPITAL MANAGEMENT LLC removed 1,241,839 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $28,239,418

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$LQDA Analyst Ratings

Wall Street analysts have issued reports on $LQDA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 12/26/2025
HC Wainwright & Co. issued a "Buy" rating on 11/04/2025
Needham issued a "Buy" rating on 11/04/2025
Jefferies issued a "Buy" rating on 08/15/2025

To track analyst ratings and price targets for $LQDA, check out Quiver Quantitative's $LQDA forecast page.

$LQDA Price Targets

Multiple analysts have issued price targets for $LQDA recently. We have seen 6 analysts offer price targets for $LQDA in the last 6 months, with a median target of $46.0.

Here are some recent targets:

Julian Harrison from BTIG set a target price of $49.0 on 12/26/2025
Andrew S. Fein from HC Wainwright & Co. set a target price of $50.0 on 11/04/2025
Serge Belanger from Needham set a target price of $52.0 on 11/04/2025
Amy Li from Jefferies set a target price of $43.0 on 08/15/2025
Ryan Deschner from Raymond James set a target price of $41.0 on 08/13/2025
Tiago Fauth from Wells Fargo set a target price of $31.0 on 08/13/2025

Full Release

MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.

Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations . The webcast will be archived on the company's website for at least 30 days.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT ^® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com .

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4400
[email protected]

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
[email protected]